Edition:
United States

Imprimis Pharmaceuticals Inc (IMMY.OQ)

IMMY.OQ on NASDAQ Stock Exchange Capital Market

1.70USD
22 Sep 2017
Change (% chg)

$0.02 (+1.19%)
Prev Close
$1.68
Open
$1.70
Day's High
$1.71
Day's Low
$1.66
Volume
10,992
Avg. Vol
39,592
52-wk High
$4.68
52-wk Low
$1.49

Chart for

About

Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through... (more)
No analyst recommendations are available for .

Overall

Beta: -0.46
Market Cap(Mil.): $34.11
Shares Outstanding(Mil.): 20.07
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 81.40 16.08
EPS (TTM): -- -- --
ROI: -- 3.18 14.60
ROE: -- 4.93 14.03

BRIEF-FDA Curcumin Investigation supports Imprimis statement

* Imprimis Pharmaceuticals Inc - ‍provided an update regarding FDA Medwatch notice issued on August 4, 2017​

Sep 14 2017

BRIEF-Imprimis Pharmaceuticals ‍responded to Allergan Plc press release regarding lawsuit

* Imprimis Pharmaceuticals Inc - ‍responded to a press release issued by Allergan Plc regarding a lawsuit Allergan USA, Inc. filed against Imprimis​

Sep 11 2017

BRIEF-Allergan USA files suits against Imprimis, Prescriber's Choice and Sincerus Florida

* Allergan files suits against Imprimis Pharmaceuticals, Inc., Prescriber's Choice, Inc., and Sincerus Florida, LLC

Sep 07 2017

BRIEF-Imprimis Pharmaceuticals Q2 earnings per share $0.07

* Imprimis pharmaceuticals announces second quarter 2017 financial results

Aug 10 2017

BRIEF-Imprimis provides statement regarding curcumin emulsion FDA medwatch notice

* Imprimis statement regarding curcumin emulsion FDA medwatch notice

Aug 07 2017

BRIEF-Imprimis Pharmaceuticals announces $16 mln debt facility with SWK Holdings

* Imprimis Pharmaceuticals announces $16 million debt facility with SWK Holdings

Jul 20 2017

BRIEF-Imprimis Pharmaceuticals sells Pennsylvania facility and sinus assets

* Imprimis Pharmaceuticals sells Pennsylvania facility and sinus assets

Jun 29 2017

BRIEF-Imprimis files for potential mixed shelf of up to $75 mln

* Imprimis pharmaceuticals inc files for potential mixed shelf of up to $75 million - sec filing Source text for Eikon: Further company coverage:

May 26 2017

BRIEF-Imprimis Pharmaceuticals announces qtrly loss per share $0.26

* Imprimis Pharmaceuticals announces first quarter 2017 financial results

May 10 2017

BRIEF-Imprimis Pharmaceuticals Q1 loss per share $0.26

* Total revenue $6.1 million in the first quarter of 2017, up 39%

May 10 2017

Competitors

  Price Chg
Eli Lilly and Co (LLY.N) $83.91 +0.58
Sanofi SA (SASY.PA) €84.12 --
Bayer AG (BAYGn.DE) €110.10 --
Bayer AG (BAYE.F) -- --
Roche Holding Ltd. (ROG.S) CHF248.00 --
Roche Holding Ltd. (RO.S) CHF248.00 --
Merck & Co., Inc. (MRK.N) $65.13 -0.47
Novartis AG (NOVN.S) CHF83.45 --

Earnings vs. Estimates